In the field of biomedicine, the concepts of precision medicine and individualized therapy are gaining increasing attention. In order to achieve this goal, scientists are constantly looking for animal models that are closer to human diseases. The iHuPDX in vivo pharmacodynamic model of InnoModels Biotechnology was born in such a background, and provides a brand new perspective and tool for tumor drug research and development with its unique advantages.
1. Accurate simulation of human tumors
The iHuPDX model (i.e., "patient-derived xenograft model") uses patient tumor tissues directly transplanted into immunodeficient mice, which maintains the original structure, heterogeneity, and microenvironment of the tumor tissues to the greatest extent possible. This accurate simulation capability makes the iHuPDX model highly realistic in reflecting the biological characteristics of human tumors and drug responses.
2. Highly individualized
Each iHuPDX model is built based on the patient's tumor tissue, and therefore has highly individualized characteristics. This individualized model can not only be used to study the tumor characteristics of a specific patient, but also to tailor the treatment plan for each patient, realizing true precision medicine.
3. Powerful drug screening capability
The iHuPDX model provides an efficient in vivo screening platform for drug development. By observing the tumor response to drugs in mice, researchers can quickly screen potential drug candidates, greatly reducing the time and cost of drug development.

4. Predicting clinical trial results
An important advantage of the iHuPDX model is its ability to predict the efficacy of drugs in clinical trials. Through early evaluation of candidate drugs in the model, researchers can screen out the most likely successful drugs into clinical trials, thus improving the success rate of clinical trials.
5、Promote translational medical research
The iHuPDX model promotes the development of translational medicine as a bridge between basic research and clinical applications. Through the model, researchers can more deeply understand the biological characteristics of tumors and the mechanism of drug action, and provide more scientific and reliable therapeutic suggestions for the clinic.
6 VI. Ethics and Feasibility
Compared with traditional animal models, the iHuPDX model uses the patient's own tumor tissues, so it is more acceptable ethically. At the same time, the technology and process of the model establishment is quite mature, with high feasibility and reproducibility.
In summary, the iHuPDX in vivo drug efficacy model of InnoModels Biotechnology has opened up a new path for oncology drug discovery and development with its features of accurate simulation, high degree of individualization, powerful drug screening ability, prediction of clinical trial results, facilitation of translational medical research, as well as ethics and feasibility. With the continuous advancement of technology, the iHuPDX model is expected to play an increasingly important role in tumor research and clinical treatment.